DDrare: Database of Drug Development for Rare Diseases

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AVASTIN; AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung; Acetate; Avastin; BEVACIZUMAB; Bevacizumab; Bevacuzimab spray; Blood samples; Chloride; Dicynone; Doxycycline; Doxycycline Hyclate; EMEA/H/C/000712; ETAMSYLATE; Estriol; Etamsylate; Ferrous sulphate 200mg oral tablet; Floseal; Gold; Itraconazole; Mupirocin; NINTEDANIB; NaCl; Nintedanib; Nintédanib; OCTREOTIDE; OCTREOTIDE ACETATE; OFEV; Octreotide; Octreotide LAR; Other: Epistaxis charts; Other: Packing; Other: Standard Treatment; Other: Standard care; PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung; Pazopanib; Pegylated Interferon Alpha2b; Pomalidomide; Pomalidomide Oral Product; Propranolol; Propranolol treatment; RVG 18236; Ranibizumab; SODIUM CHLORIDE; SUB16402MIG; Sandostatin LAR; Sandostatin LAR 20 mg; Sclerotherapy; Sodium chloride; Soy protein isolate; Sporanox; Sterile saline; Submucosal Bevacizumab; THALIDOMIDE; THALIDOMIDE CELGENE*28CPS 50MG; TIMOLOL MALEATE; Tacrolimus; Tacrolimus (Advagraf); Tacrolimus capsule (low-dose); Tamoxifen; Thalidomide; Timolol; Timolol Alcon 0.5% collyre; Timolol Gel; Timolol nasal spray; Topical timolol maleate; Tranexamic Acid; Tranexamic acid; Vit D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01408030 (ClinicalTrials.gov)	August 2011	1/8/2011	North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	North American Study of Epistaxis in HHT (NOSE)	Telangiectasia, Hereditary Hemorrhagic;Epistaxis	Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid	James Gossage	HHT Foundation International	Completed	18 Years	N/A	All	123	Phase 2	United States
2	NCT01031992 (ClinicalTrials.gov)	March 2002	11/12/2009	Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia	Hereditary Hemorrhagic Telangiectasia	Drug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid.	University Hospital, Saarland	Pharmacia GmbH, Erlangen, Germany;Baxter Healthcare Corporation	Completed	18 Years	N/A	Both	23	Phase 3	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01408030
(ClinicalTrials.gov)

August 2011

1/8/2011

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

North American Study of Epistaxis in HHT (NOSE)

Telangiectasia, Hereditary Hemorrhagic;Epistaxis

Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid

James Gossage

HHT Foundation International

Completed

18 Years

N/A

All

123

Phase 2

United States

NCT01031992
(ClinicalTrials.gov)

March 2002

11/12/2009

Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia

Drug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid.

University Hospital, Saarland

Pharmacia GmbH, Erlangen, Germany;Baxter Healthcare Corporation

Completed

18 Years

N/A

Both

Phase 3

Germany